Clinical trials
Follicular Lymphoma Grade 3B clinical trials
Below are recruiting follicular lymphoma grade 3b clinical trials, each written for real people, not researchers. We’re tracking 40 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06834373RecruitingPhase 2
Golcadomide and rituximab before CAR T for lymphoma
This trial tests a combination of two medications (golcadomide and rituximab) as a short-term treatment to shrink lymphoma before you receive CAR T-cell therapy. The goal is to make the CAR T treatment more effective for people whose lymphoma has come back or hasn't responded to previous treatments.
Scottsdale, ArizonaAges 18 years+ - NCT07098364RecruitingPhase 1/Phase 2
ST-067 with CAR T-cell therapy for large B-cell lymphoma
This trial tests a new drug, ST-067, combined with a CAR T-cell therapy (liso-cel) for people with large B-cell lymphoma that has come back or not responded after at least two prior treatments. The goal is to see if the combination is safe and effective.
Seattle, WashingtonAges 18 years+ - NCT07299149RecruitingPhase 2
Testing a new triple-drug combination for untreated follicular lymphoma
This trial tests a combination of three drugs (zanubrutinib, obinutuzumab, and lenalidomide) as a first treatment for follicular lymphoma. The goal is to see if this triple therapy works safely and effectively.
Tianjin, Tianjin MunicipalityAges 18–90 - NCT07502118RecruitingPhase 2/Phase 3
NexCAR19 for B-cell blood cancers that came back
This trial tests NexCAR19 (a CAR-T cell therapy) for people with certain types of B-cell lymphoma or B-cell acute lymphoblastic leukemia that didn't respond to or came back after other treatments. It aims to see if this therapy can help control the cancer.
AnkaraAges 18 years+ - NCT07545603RecruitingPhase 2
XNW5004 tablets for hard-to-treat follicular lymphoma
This study tests a new tablet called XNW5004 in patients with follicular lymphoma (a type of blood cancer) that has come back or stopped responding after multiple prior treatments. The goal is to see if this drug can help control the cancer in patients who have limited options.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06284122RecruitingPhase 3
New drug combo vs standard chemo for untreated follicular lymphoma
This study tests a new combination of two drugs (mosunetuzumab and lenalidomide) compared to standard chemo-immunotherapy for people with newly diagnosed follicular lymphoma that needs treatment. It aims to see if the new combination works better and has fewer side effects.
GrazAges 18 years+ - NCT06549595RecruitingPhase 3
Testing a new drug combo for untreated follicular lymphoma
This study tests a new combination of two drugs (surovatamig and rituximab) for people with follicular lymphoma who have not been treated before. The goal is to see if this combination works better than standard treatments.
Huntsville, AlabamaAges 18–130 - NCT06340737RecruitingPhase 1
CD22-targeting CAR T cells for relapsed B cell lymphoma
This trial tests whether giving modified immune cells (CAR T cells) that target CD22 on cancer cells can help people with certain B-cell lymphomas that have come back or not responded to at least two prior treatments. The goal is to see if this approach can shrink tumors or control the disease.
Palo Alto, CaliforniaAges 18 years+ - NCT06350318RecruitingPhase 2
Rituximab and Zanubrutinib for slow-growing B-cell lymphomas
This trial tests a combination of two targeted drugs (rituximab and zanubrutinib) for people with slow-growing B-cell lymphomas like marginal zone or follicular lymphoma. It may be a good option if you haven't had treatment for your lymphoma before and your disease needs therapy to manage symptoms.
Tampa, FloridaAges 18 years+ - NCT05849857RecruitingPhase 2
Mosunetuzumab for follicular lymphoma that came back quickly
This Phase 2 study tests mosunetuzumab, an antibody treatment, for people with follicular lymphoma that relapsed (came back) or progressed soon after first treatment. It may help shrink the cancer again after early relapse or lack of response to standard therapy.
HelsinkiAges 18 years+ - NCT04669171RecruitingPhase 1/Phase 2
Vaccine treatment for slow-growing lymphoma, alone or combined
This trial tests a new vaccine medicine (EO2463) to treat indolent non-Hodgkin lymphoma (slow-growing lymphoma), either by itself or with other treatment. It may help your immune system recognize and attack lymphoma cells.
Boston, MassachusettsAges 18 years+ - NCT07029217RecruitingPhase 3
Lower radiation dose study for B-cell lymphomas
This study tests if a reduced dose of radiation therapy works well for certain types of B-cell lymphomas, specifically follicular lymphoma and marginal zone lymphoma. It aims to minimize side effects while still controlling the disease.
Basking Ridge, New JerseyAges 18 years+ - NCT07548697RecruitingEarly Phase 1
Safety study of CT1182 for relapsed B-cell lymphoma
This early-stage trial tests a new drug called CT1182 for B-cell non-Hodgkin lymphoma that has come back or stopped responding to prior treatment. The study will measure how safe the drug is, how well it works, and how your body processes it.
Wuhan, HubeiAges 18–75 - NCT06794268Recruiting
Long-term health study for people with lymphoma treated with liso-cel
This study looks at patients with a type of lymphoma (follicular lymphoma) who have already received a CAR T-cell therapy called liso-cel. Researchers want to track their health over time and see how well the treatment works and how safe it is in routine medical care.
Milwaukee, WisconsinAges 18 years+ - NCT06911502RecruitingPhase 3
Golcadomide plus rituximab for relapsed follicular lymphoma
This trial tests a new drug, Golcadomide, combined with rituximab, for people with follicular lymphoma that has come back or hasn't responded to prior treatment. The goal is to see if this combination works better than other treatments your doctor might choose.
Birmingham, AlabamaAges 18 years+ - NCT05899621Recruiting
Study of obinutuzumab-based treatment for untreated follicular lymphoma
This real-world study looks at how well obinutuzumab-based treatment works for people with newly diagnosed follicular lymphoma. It is meant for patients whose cancer is measurable on scans and who are eligible for specific standard treatment combinations.
Shanghai, Shanghai MunicipalityAges 18 years+
Hear when a new Follicular Lymphoma Grade 3B trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for follicular lymphoma grade 3b?
- Yes. Clin2 currently lists 40 recruiting follicular lymphoma grade 3b studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a follicular lymphoma grade 3b trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a follicular lymphoma grade 3b trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.